Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Looking for a good area in which to invest? Consider the healthcare sector. People must have healthcare. And with aging ...
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...
GlobalData on MSN8h
Struggling bluebird bio to go private for less than $30m
Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and Drug Administration (FDA)-approved gene therapy products, including Zynteglo ...